Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon d...
Q1 2026
May 12, 2026
FY 2025
Mar 6, 2026
Q4 2025
Q3 2025
Nov 6, 2025
Q2 2025
Aug 12, 2025